ALKERMES | ALKS - Interest Expense On Debt


ALKERMES reported $27.55M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 27.55M 1.63M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 316M 201.3M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 4M 14M Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Otsuka Holdings JPY 8.54B 6.32B Sep/2026
Ovoca Bio EUR 7K 6K Jun/2022
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026